Progyny (NASDAQ:PGNY) Releases FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.520-1.620 for the period, compared to the consensus estimate of 1.660. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q1 2025 guidance to 0.440-0.470 EPS.

Progyny Trading Down 0.5 %

NASDAQ PGNY traded down $0.12 on Thursday, reaching $22.88. 2,306,329 shares of the company were exchanged, compared to its average volume of 1,776,190. The business’s fifty day moving average price is $20.34 and its 200 day moving average price is $18.65. The stock has a market capitalization of $1.95 billion, a P/E ratio of 39.45, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $38.98.

Analyst Ratings Changes

PGNY has been the subject of several recent analyst reports. Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Truist Financial restated a “hold” rating and issued a $19.00 price objective (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Canaccord Genuity Group dropped their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Barclays lowered their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. boosted their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Progyny has a consensus rating of “Hold” and a consensus target price of $25.83.

Insider Activity at Progyny

In other news, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.